Understand the source comparison
Peptides for Joint Health: Type Comparison
BPC-157 FAK-paxillin pathway activation, VEGF/bFGF upregulation, MMP-9 inhibition Preclinical models show 38–43% improvement in tendon healing and cartilage preservation; no Phase 3 human trials 200–500 mcg daily subcutaneous injection near injury site Subcuta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- FAK-paxillin pathway activation, VEGF/bFGF upregulation, MMP-9 inhibition
- Preclinical models show 38–43% improvement in tendon healing and cartilage preservation; no Phase 3 human trials
- 200–500 mcg daily subcutaneous injection near injury site
- Subcutaneous or intramuscular
- Strongest preclinical evidence for soft tissue and cartilage repair; limited human safety data requires cautious application
- TB-500 (Thymosin Beta-4)
- G-actin binding, chondrocyte migration, ECM deposition, angiogenesis via VEGF
- University of Oxford: 52% cartilage lesion reduction in OA models; veterinary use documented extensively
- 2–5 mg twice weekly (loading), 2 mg weekly (maintenance)
- Proven track record in veterinary sports medicine; human applications extrapolated from animal data—efficacy plausible, controlled trials absent
- GHK-Cu
- Collagen gene expression, lysyl oxidase activation, copper-dependent matrix cross-linking
- Phase 2 trial: 41% increase in type I collagen mRNA in osteoarthritic knees; topical formulation tested
- 1–3 mg oral daily or topical application 2–3× weekly
- Oral, topical, or subcutaneous
- Safest peptide profile due to endogenous origin; effect magnitude lower than BPC-157/TB-500 but better human safety documentation
- Cartalax
- Epigenetic regulation of cartilage-specific gene clusters
- Russian Institute of Bioregulation studies show improved joint mobility scores; Western peer-reviewed validation limited
- 10–20 mg daily sublingual or injection for 10–30 days
- Sublingual or subcutaneous
- Emerging peptide bioregulator class; mechanism distinct from growth factor peptides—promising but requires independent replication
- Pentosan Polysulfate (PPS)
- Glycosaminoglycan synthesis, anti-inflammatory, MMP inhibition
- FDA-approved for interstitial cystitis; off-label joint use shows 30–40% pain reduction in equine OA studies
- 100–250 mg intramuscular weekly (human extrapolation)
- Intramuscular injection
- Not a peptide (polysaccharide) but grouped in joint therapy protocols; established safety profile but efficacy in humans less documented than veterinary